ALTERNATING CHEMORADIOTHERAPY WITH CISPLATIN AND 5-FLUOROURACIL PLUS BLEOMYCIN BY CONTINUOUS INFUSION FOR LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE

被引:38
|
作者
AZLI, N
ARMAND, JP
RAHAL, M
WIBAULT, P
BOUSSEN, H
ESCHWEGE, F
SCHWAAB, G
GASMI, J
BACHOUCHI, M
CVITKOVIC, E
机构
[1] INST GUSTAVE ROUSSY, UNITE LA GRANGE VILLEJUIF, F-77176 VILLEJUIF, FRANCE
[2] INST SALAH AZAIZ, TUNIS, TUNISIA
[3] CTR ANTI CANC BENBADIS, CONSTANTINE, ALGERIA
关键词
D O I
10.1016/0959-8049(92)90005-M
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
More than 80% of undifferentiated carcinoma nasopharyngeal type patients with N3 disease (AJC-UICC 1987) will die with or from distant metastases within 3 years after the first symptom. From February 1986 to November 1987 30 consecutive patients with very advanced local disease were entered in a programme with chemotherapy-radiotherapy (CT-RT) alternation after a thorough work-up to eliminate the possibility of distant metastases. Protocol: two cycles of cisplatin 100 mg/m2 day 1, bleomycin 15 mg intravenously day 1 and 16 mg/m2 per day by continuous infusion days 1-5; 5-fluorouracil (5-FU) 650 mg/m2 per day by continuous infusion days 1-5 4 weeks apart. This was followed by two series of high-energy radiotherapy, 35 Gy/3.5 weeks, with a third chemotherapy cycle in between. 27 men and 3 women were treated, the median age was 37 years (range 17-71) and the mean WHO performance status was 1 (range 0-3). TNM classification: 15 T4, 9 T3, 6 T2, 28 N3 and 2 N2c. 18 patients had nodes larger than 8 cm and 24 had bulky bilateral cervical nodes. Toxicity for this protocol was moderate, nausea and vomiting being the main side-effects. Results after two CT cycles were 3 complete responses (CR; 10%), 22 partial responses (PR; 73%), 2 disease stabilisations, 2 progressions, and 1 patient inevaluable. Of the 30 patients, 27 patients completed the CT-RT protocol, 2 patients died before radiotherapy and 1 refused treatment after 2 days on protocol. 25 patients were in CR 3 months after the end of radiotherapy. As of August 1991, with a median follow-up of 55 months (range 43-63), there are 17 patients alive, 2 of them with active disease and 15 are NED (2 after salvage therapy).
引用
收藏
页码:1792 / 1797
页数:6
相关论文
共 50 条
  • [21] Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma
    El-Hadaad H.A.
    Wahba H.A.
    Roshdy S.
    Journal of Gastrointestinal Cancer, 2015, 46 (2) : 156 - 160
  • [22] CISPLATIN PLUS CONTINUOUS INFUSION OF 5-FLUOROURACIL FOR 5 DAYS EFFECTIVE FOR PATIENTS WITH ADVANCED GASTRIC-CANCER
    OKADA, Y
    ANAI, H
    HATTORI, T
    MAEHARA, Y
    NISHIMURA, J
    SUGIMACHI, K
    NAWATA, H
    ANTI-CANCER DRUGS, 1991, 2 (05) : 453 - 456
  • [23] Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil
    Hsu, CH
    Yeh, KH
    Lui, LT
    Lee, YC
    Bu, CF
    Wang, HP
    Lin, JT
    Cheng, AL
    ANTICANCER RESEARCH, 1999, 19 (5C) : 4463 - 4467
  • [24] Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5 FU) and cisplatin for locally advanced resectable esophageal cancer: A retrospective study
    Almhanna, Khaldoun
    Hoffe, Sarah
    Shridhar, Ravi
    Strosberg, Jonathan R.
    Dinwoodie, William R.
    Meredith, Kenneth
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [25] Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer
    Thukral, A.
    Metz, J.
    Hwang, W. -T.
    O'Dwyer, P.
    Plastaras, J.
    Both, S.
    Bar Ad, V.
    DISEASES OF THE ESOPHAGUS, 2011, 24 (05) : 330 - 336
  • [26] A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma—the ESO-shanghai 1 trial protocol
    Yun Chen
    Zhengfei Zhu
    Weixin Zhao
    Ling Li
    Jinjun Ye
    Chaoyang Wu
    Huarong Tang
    Qin Lin
    Jiancheng Li
    Yi Xia
    Yunhai Li
    Jialiang Zhou
    Kuaile Zhao
    Radiation Oncology, 13
  • [27] Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer
    Masashi Hashimoto
    Yasuhiro Shirakawa
    Naoaki Maeda
    Shunsuke Tanabe
    Kazuhiro Noma
    Kazufumi Sakurama
    Kuniaki Katsui
    Masahiko Nishizaki
    Toshiyoshi Fujiwara
    Esophagus, 2020, 17 : 127 - 134
  • [28] Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer
    Hashimoto, Masashi
    Shirakawa, Yasuhiro
    Maeda, Naoaki
    Tanabe, Shunsuke
    Noma, Kazuhiro
    Sakurama, Kazufumi
    Katsui, Kuniaki
    Nishizaki, Masahiko
    Fujiwara, Toshiyoshi
    ESOPHAGUS, 2020, 17 (02) : 127 - 134
  • [29] INTERFERON COMBINED 5-FLUOROURACIL PLUS CISPLATIN HEPATIC ARTERIAL INFUSION IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Yamashita, Tatsuya
    Arai, Kuniaki
    Sunagozaka, Hajime
    Ueda, Teruyuki
    Mizukoshi, Eishiro
    Sakai, Akito
    Nakamoto, Yasunari
    Honda, Masao
    Kaneko, Shuichi
    HEPATOLOGY, 2009, 50 (04) : 1093A - 1093A
  • [30] Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma
    Djellali, L.
    Larbaoui, B.
    Boukerche, A.
    Ghazi, S.
    Chaiba, I.
    Meziane, N.
    Yekrou, D.
    Youcef, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)